Adaptive Biotechnologies Corporation Company Profile
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 26.09 0.00%
Adaptive Biotechnologies at a glance
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Seattle, WA. Adaptive Biotechnologies is led by Mr. Chad M. Robins M.B.A. and employs about 624 people. The company's shares have traded publicly since 2019.
At a market capitalization of $4.19 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001478320, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Business description based on the company's public filings.
Company information
- Legal name
- Adaptive Biotechnologies Corporation
- Ticker
- NASDAQ: ADPT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Chad M. Robins M.B.A.
- Employees
- 624
- Headquarters
- 1165 Eastlake Avenue East, Seattle, WA, United States
- Phone
- 206 659 0067
- Website
- adaptivebiotech.com
- IPO year
- 2019
- Market cap
- $4.19B
- SEC CIK
- 0001478320
Companies similar to Adaptive Biotechnologies
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RLAYRelay Therapeutics Inc. | 17.41 | -3.01% | $3.82B | vs ADPT |
| CRSPCRISPR Therapeutics AG | 50.44 | -3.65% | $4.88B | vs ADPT |
| TARSTarsus Pharmaceuticals Inc. | 72.22 | -1.89% | $3.38B | vs ADPT |
| SRRKScholar Rock Holding Corporation | 42.20 | 0.00% | $5.14B | vs ADPT |
| DNLIDenali Therapeutics Inc. | 18.67 | -2.56% | $2.98B | vs ADPT |
| CGONCG Oncology Inc. | 63.26 | +1.41% | $5.61B | vs ADPT |
| BEAMBeam Therapeutics Inc. | 24.60 | -0.69% | $2.54B | vs ADPT |
| KODKodiak Sciences Inc | 94.26 | +3.49% | $5.92B | vs ADPT |